tbuckley/cabot-search huggingface dataset:
FOLFOX rechallenge versus regorafenib in patients with metastatic colorectal cancer refractory to standard chemotherapy: A retrospective analysis.
Authors: Maria Alessandra Calegari, Ina Valeria Zurlo, Brunella Di Stefano, Floriana Camarda, Carmela Di Dio, Giovanna Garufi, Alessandra Cassano, Carlo Antonio Barone, Emilio Bria, Michele Basso, Armando Orlandi
Journal: Journal of Clinical Oncology (2019)

669 Background: Nowadays the optimal treatment for mCRC beyond second line is still questioned. During last years, regorafenib and TAS-102 showed to improve survival compared to best supportive care in pts with refractory mCRC. Recently, some retrospective analyses compared the efficacy and safety of regorafenib and TAS-102 reporting no significant differences in survival and response outcomes. In real-world clinical practice, chemotherapy (CT) rechallenge is often considered for refractory mCRC. However, evidences regarding CT rechallenge is limited and no study has previously compared such approach with the recently approved antineoplastic agents in late lines. The aim of this study was to compare the efficacy between CT rechallenge and regorafenib in pts with refractory mCRC. Methods: This is a mono-institutional retrospective study. We compared the efficacy of FOLFOX rechallenge and regorafenib in pts with mCRC refractory to at least 2 lines of standard CT, treated at Fondazione Policlinico Universitario “A. Gemelli”-IRCCS between Jan-10 and Jan-18. The primary endpoint was OS. Secondary endpoints were RR and PFS. Results: One hundred thirty-one pts received regorafenib and 43 FOLFOX rechallenge. OS was significantly higher with FOLFOX rechallenge than it was with regorafenib (13 vs. 6 months; HR 0.67, 95% CI 0.33-0.66; p = 0.0002). PFS was significantly higher in the FOLFOX rechallenge group compared to the regorafenib group (5 vs. 3 months; HR 0.64, 95% CI 0.46-0.89; p = 0.0073). Accordingly, RR was better in pts receiving FOLFOX rechallenge compared to regorafenib (25 vs. 3%; Chi-square p &lt; 0.0001). Conclusions: Our study, although retrospective and small-sized, compared for the first time to our knowledge the efficacy of CT rechallenge to regorafenib in refractory mCRC. In our analysis, CT rechallenge with FOLFOX proved to be superior compared to regorafenib, with a survival and response benefit in pretreated mCRC. The survival benefit observed for rechallenge might be explained by the significantly higher tumor shrinkage achieved with CT rechallenge compared to regorafenib. Our results warrant further confirmation in wider and/or prospective analyses.
Long‐term outcome in patients with Takotsubo syndrome presenting with severely reduced left ventricular ejection fraction
Authors: Rodolfo Citro, Ilaria Radano, Guido Parodi, Davide Di Vece, Concetta Zito, Giuseppina Novo, Gennaro Provenza, Michele Bellino, Costantina Prota, Angelo Silverio, Francesco Antonini‐Canterin, Fausto Rigo, Olga Vriz, Gennaro Galasso, Eduardo Bossone, Jorge Salerno‐Uriarte, Federico Piscione
Journal: European Journal of Heart Failure (2019)
Abstract 21395: The One-Stop Trans-Apical Device for Aortic Valvular Disease: 1-Year Results of the Multi-Centre Study on J-Valve System
Authors: Ming Wui Tung, Wei Wang
Journal: Circulation (2017)

Objectives: This study presents the first report of multi-centre outcomes of the J-Valve TM system with a novel designed positioning element and a two-step positioning mechanism for easy and accurate implantation in patients with AS or AR. Methods: This multi-centre, prospective study, conducted at three largest cardiac centers in China, enrolled 107 patients (mean age 74.4 ± 5.18). Preoperative Euro-SCORE was (27.5 ± 8.3%). Clinical and echocardiographic evaluations were performed at baseline, post-procedure, discharge and 30 days, and also at 6 and 12 months. Results: TA-TAVI with the J-Valve device was successfully implanted in 98 patients (procedural success rate 93.33%). The overall mortality at 30 days and 12months was 4.7% and 5.0% respectively. Conversion to surgery was necessary in 6 patients (5.6%). Among 58 patients with AS, 12-month follow-up echocardiography demonstrated a favorable reduction of mean transvalvular gradients from 51±17 mmHg to 15±8 mmHg. All patients with completed follow up (n=93) reported improvements in at least one of the NYHA classes. The majority of successfully treated patients remained no or mild paravalvular aortic regurgitation (98.7%); none of the patients had severe post-procedural regurgitation (&gt;2+). The combined ratio of successful implantation without adverse events at 1-year was 85.0%. Conclusions: Transapical J-ValveTM implantation was safe and effective in the treatment of patients with AS or AR at high risk for surgery. Excellent hemodynamic performance during the one year follow-up was demonstrated with low incidence of post-operative complications.
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
Authors: Loretta J Nastoupil, Matthew A Lunning, Julie M Vose, Marshall T Schreeder, Tanya Siddiqi, Christopher R Flowers, Jonathon B Cohen, Jan A Burger, William G Wierda, Susan O'Brien, Peter Sportelli, Hari P Miskin, Michelle A Purdom, Michael S Weiss, Nathan H Fowler
Journal: The Lancet Haematology (2019)
Cultivating a Research-Ready Dialysis Community
Authors: Jennifer E. Flythe, Julia H. Narendra, Tandrea Hilliard, Karen Frazier, Kourtney Ikeler, Andrew Amolegbe, Denise Mitchell, Adeline Dorough, Shoou-Yih Daniel Lee, Antoinette Ordish, Caroline Wilkie, Laura M. Dember
Journal: Journal of the American Society of Nephrology (2019)

Individuals with kidney failure receiving dialysis have high morbidity and mortality rates and their condition is associated with poor health-related quality of life.[1][1] To address these unacceptably poor outcomes, the nephrology community has called for innovation in dialysis therapy and
FGFR2-altered gastroesophageal adenocarcinomas (GEA) are a rare clinicopathologic entity with a distinct genomic landscape.
Authors: Samuel Jacob Klempner, Russell Madison, Jeffrey S. Ross, Vincent A. Miller, Siraj Mahamed Ali, Alexa Betzig Schrock, Jeeyun Lee, Seung Tae Kim, Joseph Chao
Journal: Journal of Clinical Oncology (2019)

72 Background: Therapies directed at receptor tyrosine kinases (RTKs) in GEA have met with limited success. The small molecule FGFR2 inhibitor AZD4547 failed in a phase II biomarker-selected trial, though activity has been seen with FGFR2-directed strategies, including monoclonal antibodies. Despite observed activity, very little is known about the genomic landscape of FGFR2-altered GEA. Using a large genomic database, we sought to examine the classes of FGFR2 alterations and frequency of co-occurring alterations in GEA. Methods: 6,667 tissue specimens from unique patients with advanced GEA were assayed using hybrid capture-based comprehensive genomic profiling (CGP). Tumor mutational burden (TMB) was determined on up to 1.1 Mbp of sequenced DNA and microsatellite instability (MSI) was determined on 95 or 114 loci. Descriptive statistics were used to compare among subgroups. Results: We identified a total of 269 (4.0%) FGFR2-altered cases consisting of FGFR2 amplified (amp; 209, 78% of FGFR2-altered), FGFR2 mutated (mut; 40, 15%) and FGFR2 rearranged (re, 37, 14%). There was a female predominance in FGFR2-altered cases (M:F = 1.6:1) vs FGFR wild-type (WT) (2.8:1). Cases with FGFR2amp and FGFR2re were exclusively MS-stable. The most common fusion partner was TACC2 (22%). FGFR2amp GEA had higher rates of TP53 mutation versus either FGFR2re of FGFR2mut cases (p = 4.4E-6). Co-occurring alterations in the other GEA RTK targets including ERBB2 (10%) , EGFR (8%) and MET (3%) were observed in all types of FGFR2-altered GEA. Co-occurring downstream alterations in MYC (17%), KRAS (10%) and PIK3CA (5.6%) were observed frequently in each class of FGFR2-altered GEA. The median TMB for FGFR2-altered GEA was 3.6 mut/mb, which was not significantly different from a median of 4.3 mut/mb seen in FGFR2 WT samples (p = 0.53). Conclusions: FGFR2-altered GEA is a heterogenous subgroup with approximately 20% of FGFR2-altered samples harboring concurrent RTK alterations. Putative co-occurring modifiers of FGFR2 directed therapy including oncogenic MYC, KRAS, PIK3CA alterations were also frequent, suggesting that pre-treatment CGP and combination approaches may be needed to optimize patient selection.
Abstract 14953: Trends and Outcomes of Infective Endocarditis Treated With Mitral Valve Replacement Compared to Mitral Valve Repair: Insight From Nationwide Inpatient Sample
Authors: Sami Aljohani, Fahad Alqahtani, Ahmad Almustafa, Mohamad Adnan Alkhouli
Journal: Circulation (2017)

Background: The incidence of infective endocarditis (IE) has increased over the past two decades, available evidence comparing Mitral Valve Replacement (MVR) to Mitral Valve Repair (MVr) showed no significant difference in mortality and major morbidities. We sought to compare the trend and outcome of MVR to MVr using the Nationwide Inpatient Sample (NIS). Methods: The NIS was utilized to identify 4,724 infective endocarditis patients who underwent MVR or MVr between 2004-2013. 3659 patients underwent MVR (77.5%). A multivariable logistic regression derived propensity scores were sequenced and matched 1:1 without replacement to a caliper distance of 0.01 to attain 1048 matched pairs of patients treated with MVR or MVr to assess in-hospital outcomes. Trends assessed utilizing the Mann-Kendall test. Results: Over the period of the study, utilization of MVR and MVr showed significant upward trend (p=0.009, p=0.001 respectively) with no significant changes in mortality trends (p=0.653, p=0.522, respectively). ...
A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors
Authors: Dominic H. Banda, Paula M. Perin, Richard J.P. Brown, Daniel Todt, Wladimir Solodenko, Patrick Hoffmeyer, Kamlesh Kumar Sahu, Michael Houghton, Philip Meuleman, Rolf Müller, Andreas Kirschning, Thomas Pietschmann
Journal: Journal of Hepatology (2019)
Ascorbic acid–induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma
Authors: Niraj Shenoy, Tushar D. Bhagat, John Cheville, Christine Lohse, Sanchari Bhattacharyya, Alexander Tischer, Venkata Machha, Shanisha Gordon-Mitchell, Gaurav Choudhary, Li-Fan Wong, LouAnn Gross, Emily Ressigue, Bradley Leibovich, Stephen A. Boorjian, Ulrich Steidl, Xiaosheng Wu, Kith Pradhan, Benjamin Gartrell, Beamon Agarwal, Lance Pagliaro, Masako Suzuki, John M. Greally, Dinesh Rakheja, R. Houston Thompson, Katalin Susztak, Thomas Witzig, Yiyu Zou, Amit Verma
Journal: Journal of Clinical Investigation (2019)

Although clear cell renal cell carcinoma (ccRCC) has been shown to result in widespread aberrant cytosine methylation and loss of 5-hydroxymethylcytosine (5hmC), the prognostic impact and therapeutic targeting of this epigenetic aberrancy has not been fully explored. Analysis of 576 primary ccRCC samples demonstrated that loss of 5hmC was strongly associated with aggressive clinicopathologic features and was an independent adverse prognostic factor. Loss of 5hmC also predicted reduced progression-free survival after resection of nonmetastatic disease. The loss of 5hmC in ccRCC was not due to mutational or transcriptional inactivation of ten eleven translocation (TET) enzymes, but to their functional inactivation by l-2-hydroxyglutarate (L2HG), which was overexpressed due to the deletion and underexpression of L2HG dehydrogenase (L2HGDH). Ascorbic acid (AA) reduced methylation and restored genome-wide 5hmC levels via TET activation. Fluorescence quenching of the recombinant TET-2 protein was unaffected by L2HG in the presence of AA. Pharmacologic AA treatment led to reduced growth of ccRCC in vitro and reduced tumor growth in vivo, with increased intratumoral 5hmC. These data demonstrate that reduced 5hmC is associated with reduced survival in ccRCC and provide a preclinical rationale for exploring the therapeutic potential of high-dose AA in ccRCC.
Abstract 17906: Usefulness of a New Proposed TNM-Like Classification for Heart Failure Staging: Comparison With the Classic NYHA
Authors: Paolo Severino, Simone Calcagno, Maria Alfarano, Mariateresa Pucci, Ilaria Ferrari, Danilo Alunni Fegatelli, Annarita Vestri, Massimo Mancone, Susanna Sciomer, Francesco Fedele
Journal: Circulation (2016)

Introduction: NYHA classification is the most used for heart failure (HF), but it does not comprehend clinical features and other organs involvement due to HF. Hypothesis: We propose a staging syst...
Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib 'On Target' Adverse Events
Authors: Jorge E. Cortes, Cristina Papayannidis, Catriona Jamieson, Gary J. Schiller, Anna Candoni, Brian Leber, Claudia D. Baldus, José A. Pérez-Simón, Weidong Wendy Ma, Corrado Gallo Stampino, Ashleigh O'Connell, Mirjana Zeremski, Geoffrey Chan, Mikkael A. Sekeres
Journal: Blood (2018)
The novel chromatin architectural regulator SND1 promotes glioma proliferation and invasion and predicts the prognosis of patients
Authors: Lin Yu, Jinling Xu, Jing Liu, Huibian Zhang, Cuiyun Sun, Qian Wang, Cuijuan Shi, Xuexia Zhou, Dan Hua, Wenjun Luo, Xiuwu Bian, Shizhu Yu
Journal: Neuro-Oncology (2019)

Upregulation of staphylococcal nuclease domain-containing protein 1 (SND1) is a common phenomenon in different human malignant tissues. However, little information is available on the underlying mechanisms through which SND1 affects glioma cell proliferation and invasion.SND1, Ras homolog family member A (RhoA), and marker of proliferation Ki-67 (MKI67) were analyzed in 187 gliomas by immunostaining. The correlation between those markers and patients' prognoses was assessed using the Kaplan-Meier estimator. Gene Ontology, chromatin immunoprecipitation, electrophoretic mobility shift assay, and chromosome conformation capture were applied to identify SND1-activated target genes. We also used MTT, colony formation, transwell and orthotopic implantation assays to investigate SND1 function in glioma cell proliferative and invasive activity.We identified SND1 and RhoA as independent predictors of poor prognosis in glioma patients. SND1 knockdown significantly suppressed the proliferation and invasion of glioma cells. Mechanistically, we discovered that SND1 facilitated malignant glioma phenotypes by epigenetically inducing chromatin topological interaction, which activated downstream RhoA transcription. RhoA sequentially regulated expression of CCND1, CCNE1, CDK4, and CDKN1B and accelerated G1/S phase transition in glioma cell proliferation.Our findings identify SND1 as a novel chromatin architectural modifier and promising prognostic indicator for glioma classification and treatment.
Zika Virus Protease Cleavage of Host Protein Septin-2 Mediates Mitotic Defects in Neural Progenitors
Authors: Hongda Li, Laura Saucedo-Cuevas, Ling Yuan, Danica Ross, Anide Johansen, Daniel Sands, Valentina Stanley, Alicia Guemez-Gamboa, Anne Gregor, Todd Evans, Shuibing Chen, Lei Tan, Henrik Molina, Nicholas Sheets, Sergey A. Shiryaev, Alexey V. Terskikh, Amy S. Gladfelter, Sujan Shresta, Zhiheng Xu, Joseph G. Gleeson
Journal: Neuron (2019)
Abstract 13053: Dehydroascorbic Acid Therapy Attenuates Septic Cardiomyopathy In Mice
Authors: Bernard J Fisher, Ignacio Seropian, Benjamin V Tassell, Antonio Abbate, Alpha A Fowler, Ramesh Natarajan
Journal: Circulation (2010)

Background: Sepsis induces a complex response to bacterial infection, trauma, burns or abdominal surgery. Septic cardiomyopathy is a well-described complication of septic shock that is characterize...
Single-cell analysis of immune-microenvironment and immune-tumor interaction in human gastric cancers.
Authors: Michele Goh, Ze Ming Lim, Vivien Koh, Josephine Lum, Xiaomeng Zhang, Naomi McGovern, Rasha Msallam, Anis Larbi, Michael Poidinger, Florent Ginhoux, Matthew C.H. Ng, Patrick Tan, Wei Peng Yong, Jimmy Bok Yan So, Jinmiao Chen
Journal: Journal of Clinical Oncology (2019)

29 Background: The incidence rates of gastric cancer in Asia are among the highest in the world. Gastric cancer is a heterogeneous disease. The Cancer Genome Atlas and Asian Cancer Research Group provide molecular classification of gastric cancers. Recently, immunotherapy was found to be effective in selected gastric cancer patients. Despite the molecular classification, a classification system based on immune microenvironment is in need to better stratify patients for ideal immunotherapy combinations. Methods: We have performed indexed-sorting single cell RNA-seq to analyze both CD45+ and CD45- cells from biopsy samples of 15 gastric cancer patients (5 Diffuse; 4 Intestinal; 5 Mixed; 1 unknown type). Using our ezsinglecell analytical pipeline, we have built a draft Asian Single-cell Immune Atlas (ASIA) of human gastric cancers. Results: We were able to probe fibroblast, epithelial cells and various subtypes of immune cells. Interestingly, we observed that fibroblast and mast cells were more enriched in diffuse type. In addition, we have profiled single immune cells in tumor and normal adjacent tissues to distinguish tissue-induced versus tumor-driven immune signatures. Comparing tumor and normal tissues, we found that tumor site has less natural killer (NK) and CD8 T cells; more B, myeloid and CD4 T cells. Moreover, CD8 T cells and NK cells showed distinct phenotypes in tumor compared to normal tissues. In particular, inhibitory receptor Tim-3 and CTLA-4 were up-regulated in the tumor. Most interestingly, T Cell Receptor (TCR) reconstruction revealed clonal expansion of CD8 T cells. Conclusions: Both immune (CD45+) and non-immune (CD45-) cell components of human gastric cancers are highly heterogeneous. Diffuse type showed differential tumor microenvironment compared to intestinal and mixed types. Tumor site presented an immune-suppressive phenotype compared to normal adjacent site. The clonal expansion of CD8 T cells suggested the role of adaptive immunity on recognizing tumor antigens. This discovery may determine the clinical applications of immunotherapy for gastric cancer in the future.
Does a longer waiting period after neoadjuvant radiochemotherapy improve the oncological prognosis of rectal cancer?: Three-year follow-up results of the GRECCAR-6 randomized multicenter trial.
Authors: Jeremie H. Lefevre, Laurent Mineur, Marine Cachanado, Eric Rullier, Philippe Rouanet, Cecile De Chaisemartin, Bernard Meunier, Jafari Mehrdad, Eddy Cotte, Jérôme Desrame, Mehdi Karoui, Stephane Benoist, Sylvain Kirzin, Anne Berger, Yves Panis, Guillaume Piessen, Alain Saudemont, Michel Prudhomme, Tabassome Simon, Yann Parc
Journal: Journal of Clinical Oncology (2019)

483 Background: There are controversial data on the impact of a long waiting period between radiochemotherapy (RCT) and resection for rectal cancer on the rate of complete pathological response (pCR = ypT0N0). The impact on the oncological prognosis is also unknown. We present the 3 years survival results of the GRECCAR6 trial. Methods: The GRECCAR6 trial was a phase III, multicentre, randomized, open-label, parallel-group, controlled trial. Patients with cT3/T4 or TxN+ tumours assessed by radiological examination (MRI and/or endo-ultrasound) of the mid or lower rectum who had received RCT (45-50 Gy with intravenous 5-FU or capecitabine) were included and randomized between 7 weeks or 11 weeks of waiting period. Primary endpoint was the pCR rate. Secondary endpoints were overall, disease-free survival and rate of recurrences. Results: A total of 265 patients from 24 participating centres were enrolled between October 2012 and February 2015. Among them, 253 patients underwent surgery with mesorectal excision. The rate of pCR was 17% (43/253). Mean follow-up from surgical resection was 32±8 months. 25 deaths occurred with a 89% OS at 3 years. DFS was 67.7% at 3 years due to 77 deaths or recurrences. 3-years local and distant recurrences rates were 9.2% and 24.9%, respectively. The group of randomization had no impact on the OS (p = 0.9486) and the DFS (p = 0.8672). Distant (p = 0.8589) and local (p = 0.5780) recurrences were also not influenced by the waiting period. Patients with a pCR had an excellent prognosis with an overall survival of 94.5% versus 87.9% for the remaining patients at 3 years (p = 0.232) and a DFS of 89.6% versus 63.4% (p = 0.0025). On multivariate analysis, DFS was influenced by low rectal tumors (OR=1.74; [1.03; 2.94], p = 0.037), R1 resection (OR = 2.03; [1.18; 3.50], p = 0.011), ypT3-T4 (OR = 2.4; [1.12; 5.19], p = 0.0245) and N+ (OR = 2.85; [1.76; 4.61], p &lt; 0.001). Conclusions: Waiting 4 weeks longer after radiochemotherapy has no influence on the oncological outcomes of T3/T4 rectal cancers. Clinical trial information: NCT01648894.
Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3 Gimema-MMY-3006 Study and Prognostic Score for Survival Outcomes
Authors: Paola Tacchetti, Luca Dozza, Francesco Di Raimondo, Claudia Crippa, Elena Zamagni, Sara Bringhen, Lucia Pantani, Massimo Offidani, Vittorio Montefusco, Franco Narni, Katia Mancuso, Claudia Cellini, Antonio Spadano, Norbert Pescosta, Luca Baldini, Carolina Terragna, Chiara Nozzoli, Renato Zambello, Daniele Derudas, Stelvio Ballanti, Michele Cavo
Journal: Blood (2018)
Abstract IA02: The role of aneuploidy during tumorigenesis
Authors: Teresa Davoli
Journal: Clinical Cancer Research (2018)

Abstract Since Boveri’s postulates in 1914, aneuploidy has been recognized as a hallmark of human cancer; however, no comprehensive theory exists to explain its patterns and its role in tumor evolution. We have developed Tumor Suppressor and Oncogene (TUSON) Explorer, a computational method for the prediction of tumor suppressor genes (TSG) and oncogenes (OG) through the analysis of the pattern of somatic mutations in cancer. By integrating our prediction of TSGs and OGs with information of copy number alterations, we found that the distribution on chromosomes and the potency of TSGs and OGs can predict the frequency of arm-level and chromosome-level deletions and amplification (Davoli et al., 2013). We propose that it is the decrease or increase in the gene dosage of TSG and OG genes in deletion and amplification to determine the recurrent patterns of aneuploidy selected during tumor evolution. More recently, we have performed gene expression analysis on tumor samples, comparing tumors with different levels of aneuploidy (Davoli et al., 2017). We have found that tumors with high levels of aneuploidy show increased markers of proliferation as well as a strong decrease in infiltrating immune cells, especially CD8+ T cells. Notably, we show that aneuploidy predicts patients’ survival in two clinical trails of immunotherapy in cancer patients. Compared to neoantigen load, aneuploidy represents an independent and stronger predictor of survival. A combined score including aneuploidy and neoantigen load allows superior prediction of survival after immunotherapy. We are now investigating the mechanism by which aneuploidy affects cancer immune evasion. I will present novel data suggesting that aneuploidy may play a role in inhibiting and dysregulating antigen processing and presentation in tumor cells. Overall, our data indicate that aneuploidy is a driver event in human tumorigenesis. Citation Format: Teresa Davo4li. The role of aneuploidy during tumorigenesis [abstract]. In: Proceedings of the Fifth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic; Jan 8-11, 2018; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(17_Suppl):Abstract nr IA02.
Disease and Clinical Characteristics of Patients with Essential Thrombocythemia Enrolled in the MOST Study
Authors: Abdulraheem Yacoub, Roger M. Lyons, Srdan Verstovsek, Ryan Shao, David Tin Chu, Apurv Agrawal, Smitha Sivaraman, Philomena Colucci, Peter Yao, John Mascarenhas
Journal: Blood (2018)